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When not involved in research or clinical work, Christina spends much of her leisure time as captain of a Sabre 30 or C&C 34 sailboat, either in races around the Boston Harbour or going along the New Defining an optimal level of research funding may be difficult in the context of all the other important activities requiring funds, from education to security and justice. However, there are aspects of Research & Development (R&D) funding that can be easily identified as potentially problematic. Far from being an expert in the economics of research and health, my experience as an academic cardiologist and a scientist, indicates that actions may be required in R&D funding in general, in cardiovascular R&D funding in particular and in R&D funding in some European countries.
If we analyse allocation of funds for R&D in the world and its temporal evolution and trends, some facts can be easily appreciated.
Firstly, after a period of growth, the percentage of the Gross National Product (GNP) dedicated to R&D in countries with the highest levels of research funding, such as Japan, the USA or Germany, remain essentially stable, close to 3% of GNP. There is cause for concern that the rate of scientific advancement will be lower in the future than in previous years, where there was a continuous increase in funding levels.
Secondly, the stability in R&D funding levels is also seen in industrialized countries with lower funding levels: around 2% of GNP for the European Union. We can anticipate that the gap between R&D results in the USA and the EU will not be reduced in the near future.
Thirdly, globalization, the increasing power of big corporations and the recent economic crisis has reoriented research activity towards a more business-oriented model. Immediately applicable research and innovation are more and more preferentially funded in an attempt to translate benefits to the society but also to transform knowledge into economic value as fast as possible. But harvesting funds to the detriment of seeding may not be the best way.
Cardiovascular R&D funding has specific problems. Cardiac (not even cardiovascular) diseases are the main cause of mortality and loss of quality life years in the global population, and it is expected to keep that position at least during the next ten years. Yet cardiovascular R&D funds are not in the leading position for funds received, where cancer research is first. There are several reasons to explain the disproportionately low level of funding of cardiovascular research.
(1) The understandable human emotional factors inherently associated with cancer diseases. (2) The economic implications for drug companies of the previous factors in 1 above.
(3) The false perception among lay people and many professionals that cardiac diseases are preventable by adequate primary prevention and are in fact declining. (4) The hyper-acute nature of some of the most socially important cardiac conditions, such as acute myocardial infarction with STsegment elevation or sudden cardiac death, makes these conditions less attractive for drug companies compared to chronic conditions requiring chronic treatments. In fact, most of the recent advancements in pharmacological therapy for cardiac diseases are in fact aimed at extra-cardiac targets of chronic conditions (vasodilators, diuretics, anticoagulants, lipid-lowering drugs). (5) The late incorporation of molecular and genetic science to cardiovascular research. Also the prominent and importance of physiological studies to investigate heart diseases being physiology are an under-funded area.
It is thus important and urgent to increase cardiovascular funding to levels that correspond to the social and economic impact of cardiovascular diseases by making their social and economic importance clear to politicians and funding agencies, and the European Society of Cardiology should have a leading role in this action.
It is also important to increase public funding to develop cardiac therapies where there is a reduced perspective for economic reward. We must campaign to potentiate funding of physiological studies. There is also a need to potentiate programs aiming to bridge the gap between laboratory and clinical cardiovascular science, increase multi-discipline coordination and to attract, and retain, young talent to cardiovascular medicine.
Finally, there are large differences in the proportion of funds allocated to R&D within the EU, with several relatively large countries allocating around 1.5% or less of their GNP to R&D. As a consequence of the recent economic crisis, research funding has been further reduced in some of these countries. In Spain, for example, public funding of health and fundamental research projects has been reduced during this economic crisis by more than 25%, with fewer projects and less funds per project. As important as this, cuts in the public health system, particularly in personnel, with low replacement rates of retired physicians has imposed a progressive overload of clinical work in tertiary, university hospitals in some of these countries.
The reduction in research time available for physicians may be even more detrimental to translational research than the cutting in R&D funding. During these years, dependence on international,
